In today’s blog, it is our pleasure to introduce you to Pierre-Axel Vinot, Senior Director, CMC.
Hi Pierre-Axel, Can you tell us what is your role at SparingVision?
My role as Chemistry, Manufacturing, and Control (CMC) Director, involves leading the efforts to manufacture and bring our therapies to patients enrolled in our clinical trials. I look over the activities from the conception of the manufacturing process to guaranteeing the quality of the product, up until the moment it reaches the patient.
What inspired you to join the genomic medicine in ophthalmic industry, and what keeps you motivated?
My interest always leaned more toward immunology and genetic engineering, rather than traditional chemistry. After earning my Pharm.D, it made a lot of sense to focus my residency on developing complex biologics and start a PhD in that same field. I stay motivated because we are only in the ‘opening chapters’ of the Cell and Gene Therapy (CGT) story. The field constantly reinvents itself with annual breakthroughs, and being at the forefront of that evolution is incredibly energizing.
What do you do in your department at SparingVision?
My primary focus is designing and executing the manufacturing strategy that guarantees the highest product quality for our clinical trials. This involves orchestrating a complex network of subcontractors to produce and control our gene therapies, ensuring we not only meet strict regulatory standards but also remain agile enough to support our clinical timelines.
How do you work with different teams across the company?
CMC sits at the crossroads of our company, bridging every stage from product development to patient delivery. This journey begins with manufacturing, where we need deep expertise in vector and drug biology, and extends all the way through to patient treatment in collaboration with our clinical department and clinical sites. Because my work spans every stage of development, I’ve had the privilege of working with every department, either contributing technical expertise to help achieve their milestones, and other times learning from their specialized insights to enhance our own processes.
We always say everything at SparingVision starts with the patient. What does that mean in your role?
We are developing treatments for people facing progressive diseases that lead to blindness – conditions that currently have no cure. In my role, this is a daily reminder of our immense responsibility to provide a safe and transformative product. Beyond the science, I am deeply moved by the courage of the patients who enroll in our trials; their dedication is what drives me to ensure we do things the right way.
In a few words, why did you choose to work for SparingVision?
I’ve been lucky to join SparingVision at the very beginning of the project when everything had to be built. I thrive in fast-paced environments where I can build from the ground up. Joining an early-stage biotech company is an incredible opportunity to be hands-on in nearly every aspect of drug development.
